GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Price-to-Free-Cash-Flow

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Price-to-Free-Cash-Flow : N/A (As of May. 15, 2024)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Price-to-Free-Cash-Flow?

As of today (2024-05-15), InVivo Therapeutics Holdings's share price is $0.3805. InVivo Therapeutics Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.81. Hence, InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

NVIVQ's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.23
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

InVivo Therapeutics Holdings's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.74. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-3.81.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 79.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 79.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 57.60% per year.

During the past 13 years, InVivo Therapeutics Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 84.80% per year. The lowest was -724.80% per year. And the median was 15.90% per year.


InVivo Therapeutics Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Price-to-Free-Cash-Flow Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow falls into.



InVivo Therapeutics Holdings Price-to-Free-Cash-Flow Calculation

InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.3805/-3.809
=N/A

InVivo Therapeutics Holdings's Share Price of today is $0.3805.
InVivo Therapeutics Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


InVivo Therapeutics Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Headlines

From GuruFocus

InVivo Therapeutics Announces Closing of $15.0 Million Public Offering

By Business Wire Business Wire 10-27-2020